Company / EPS (Diluted)
Biogen EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$7.97
FY2025
5-year range
$7.97 / $31.42
FY2021-FY2025
Trend
-61.8%
vs FY2024
Sector context
#7 of 204
Health Care
What the data says
Among 204 Health Care companies, Biogen is in the top 3% for eps (diluted). EPS (Diluted) has fluctuated over the past 10 years, ranging from $7.97 in FY2025 to $31.42 in FY2021.
Based on SEC 10-K filings.
7.97 in FY2025 with a 5-year CAGR of -18.1%. Top quartile in the Health Care sector.
Declined from $10.40 to $7.97 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -31.5%
- 5-Year CAGR
- -18.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 204This company $7.97 Sector average -$1.03
▼
+872.4% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 61.8% year-over-year.
- Ranks #7 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.97 | -61.8% |
| FY2024 | $20.87 | +100.7% |
| FY2023 | $10.40 | -58.1% |
| FY2022 | $24.80 | -21.1% |
| FY2021 | $31.42 | +45.6% |
| FY2020 | $21.58 | +81.0% |
| FY2019 | $11.92 | -29.6% |
| FY2018 | $16.93 | +10.4% |
| FY2017 | $15.34 | +24.0% |
| FY2016 | $12.37 | +58.4% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026